FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML

• Status: Unknown status
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

• To determine the feasibility of fludarabine and cytarabine as continuous infusion plus idarubicin with granulocyte-colony stimulating factor priming for patients with resistant acute myeloid leukemia other than acute promyelocytic leukemia

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cooperative Study Group A for Hematology
• Treatments: Cytarabine; Fludarabine; Lenograstim

Criteria

Inclusion Criteria:

• Failure to achieve CR after initial induction chemotherapy including standard dose cytarabine.

• Early relapse, occurring after a first CR lasting less than 12 months.

• Patients with multiple relapses will be included.

• Written informed consent must be given.

• 15 and 60 years of age.

• 2 or less by ECOG performance scale.

Exclusion Criteria:

• acute promyelocytic leukemia

• pregnant or lactating